Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies.
Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies.
复制标题
DOI：
10.1517/17425240903085128
复制
发表时间：
2009-08
影响因子：
6.6
通讯作者：
Forrest ML
中科院分区：
文献类型：
--
作者：
Xie Y;Bagby TR;Cohen MS;Forrest ML
癌症是美国第二大死因。目前，癌症治疗方案包括切除病变和可疑组织的手术、聚焦放射、全身化疗、免疫疗法及其组合。在常规化疗中，几乎不可能在不损害健康器官或组织的情况下，将抗癌药物专门输送到肿瘤细胞。在过去的几十年里，人们一直在努力改进针对肿瘤细胞的抗癌药物的药物输送技术。众所周知，淋巴管是大多数实体癌的第一转移部位；然而，很少有人努力将化疗定位于淋巴组织。基于含有化疗药物的纳米粒(如脂质体阿霉素)的几种全身靶向给药系统的试验表明，与传统制剂相比，具有相似的抗肿瘤活性，但患者耐受性更好。动物研究表明，与传统的静脉疗法相比，由天然或合成聚合物和脂质体载体制成的纳米颗粒在淋巴结和周围淋巴管中的蓄积更高。这种联合治疗既有可能减少非特异性器官毒性，又有可能增加局部癌症转移部位的化疗剂量。
Cancer is the second leading cause of death in the US. Currently, protocols for cancer treatment include surgery to remove diseased and suspect tissues, focused radiation, systemic chemotherapy, immunotherapy and their combinations. With conventional chemotherapy, it is almost impossible to deliver anticancer drugs specifically to the tumor cells without damaging healthy organs or tissues. Over the past several decades, efforts have been made to improve drug delivery technologies that target anticancer drugs specifically to tumor cells. It has been known for over four decades that the lymphatics are the first site of metastasis for most solid cancers; however, few efforts have been made to localize chemotherapies to lymphatic tissues. Trials of several systemic targeted drug delivery systems based on nanoparticles containing chemotherapeutic agents (e.g., liposomal doxorubicin) have shown similar antitumor activity but better patient tolerance compared with conventional formulations. Animal studies have demonstrated that nanoparticles made of natural or synthetic polymers and liposomal carriers have higher accumulation in the lymph nodes and surrounding lymphatics compared to conventional intravenous therapies. This combination has the potential to both reduce nonspecific organ toxicities and increase the chemotherapeutic dose to the most likely sites of locoregional cancer metastasis.
登录
查看更多内容
影响因子：
5.3
作者：
Liu, J;Wong, HL;Johnston, MR
通讯作者：
Johnston, MR
影响因子：
3.8
作者：
McCarter, MD;Clarke, JH;Harken, AH
通讯作者：
Harken, AH
影响因子：
5.8
作者：
KIM, CK;LEE, MK;LEE, BJ
通讯作者：
LEE, BJ
影响因子：
3
作者：
Lu, Hongxia;Li, Bin;Xu, Congjian
通讯作者：
Xu, Congjian
影响因子：
3.5
作者：
Fujimoto, Ai;Ishikawa, Yukio;Ishii, Toshiharu
通讯作者：
Ishii, Toshiharu